Charles B. Nemeroff to speak at 2nd CNS Diseases World Summit Sept 13-14, 2012 San Francisco, CA
Charles B. Nemeroff, Leonard M. Miller Professor, Chairman and Director at the University of Miami will give a plenary keynote presentation on "Obstacles in Drug Development" at the 2nd CNS Diseases World Summit taking place on Sept 13-14, 2012 in San Francisco, CA.
- Boston, MA-NH (1888PressRelease) June 28, 2012 - In 2009 Dr. Nemeroff joined the University of Miami Leonard M. Miller School of Medicine as the Leonard M. Miller Professor and Chairman of the Department of Psychiatry and Behavioral Sciences. His research has concentrated on the biological basis of the major neuropsychiatric disorders, including affective disorders, schizophrenia, and anxiety disorders. His clinical research is focused on the use of genetic, neuroendocrine, neuroimaging and neurochemical methods to comprehensively understand the pathophysiology of depression. In recent years he has uncovered the neurobiological mechanisms that mediate the increased risk for depression in victims of child abuse. He has also contributed to seminal findings in the burgeoning area of research concerning the relationship of depression to cardiovascular disease.
Dr. Nemeroff has published more than 950 research reports and reviews, and has received numerous honors during his career. Dr. Nemeroff served as the Editor-in-Chief of Neuropsychopharmacology from 2001-2006. With Alan F. Schatzberg, MD, he is co-Editor of the Textbook of Psychopharmacology, now in its Fourth Edition, published by the American Psychiatric Press Inc. He has served on the Mental Health Advisory Council of the National Institutes of Mental Health and the Biomedical Research Council for NASA. He is past President of the American College of Neuropsychopharmacology and the American College of Psychiatrists. He is currently a member of the Board of Directors of the American Foundation for Suicide Prevention. He served as chair of the APA Committee on Research Training. In 2002 he was elected as a member of the Institute of Medicine of the National Academy of Sciences.
GTC's 2nd CNS Diseases World Summit brings together the leading experts across the industry and academia to discuss the latest research and developments in the CNS field. The summit has four parallel tracks that focus on neurodegenerative conditions, neuropsychiatric disorders, pain research and therapeutics and CNS partneriing and deal-making.
Join your colleagues at this exciting CNS summit and hear from and meet with key representatives in the field including Husseini Manji - Global Head of Neuroscience Therapeutic at Janssen, Barry Brand - Chief Executive Officer at CeNeRx, Michael W. Weiner at UCSF, George Garibaldi - Global Head of CNS Clinical Development at F. Hoffmann-La Roche, Tony W. Ho - Vice President at AstraZeneca, and many more!
For more information, please visit www.gtcbio.com